Other conferences by IBC »
You are here: Home » Speakers
Speakers

Speakers

Augustine Yee
Head of Asia Pacific Corporate and Regional Development and China Vice President of Business Development
AstraZeneca, China
Barry Bernstein, MD
Global Head of Infectious Disease Development
Abbott Laboratories, USA
Binhui (Ben ) Ni
Head of Scouting & Partnership
Sanofi Aventis,
China
Kwanghyouk Lee
General Manager
SK biopharmaceuticals (Shanghai), China
Carl Firth
Chief Executive Officer
ASLAN Pharmaceuticals, Singapore
Zhi-Qiang Ning, MD, PhD
Cofounder, VP R&D
Shenzhen Chipscreen Biosciences Ltd, China
Chen Chen
CEO
Sundia MediTech, China
David G. Wang, MD, PhD
Senior Managing Director
OrbiMed Asia,
China
Dianna Qian
Principal
FIL Capital Management,
China
Frank Shen
Divisional Vice President, Statistics & Data Management
Abbott Laboratories,
USA
Guoqing Cao
Vice President of Biology
Jiangsu Hengrui Medicine, China
Ian Lloyd
Senior Director, Pharmaprojects/Pipeline and Data Integration
CiteLine, UK
Jun Bao
Director of Worldwide Business Development
GlaxoSmithKline, China
James Garner, MD
Vice President and General Manager
Takeda Global Research and Development Center (Asia),
Singapore
James Huang
Managing Partner
KPCB, China
Jason Mann
Head China Healthcare Equity Research
Barclays Capital,
Hong Kong
Jim O’Mara
Vice President Corporate Development
Ironwood Pharmaceuticals,
USA
Ka-Kit Hui, MD, FACP
Wallis Annenberg Chair in Integrative East-West Medicine, Chair, Collaborative Centers for Integrative Medicine, Professor, Founder & Director
Center for East-West Medicine, Department of Medicine, UCLA,
USA
Mikael Brönnegård, MD, PhD
Associate Professor, and Chief Executive Officer
NeuroVive Pharmaceutical AB,
Sweden
Ming Guo, PhD
Co-Founder & COO, Ascentage Pharma
and General Manager, Small Molecule Drug R&D Center, China Medical City, China
Pui-Kwong Chan, PhD
Professor, Department of Pharmacology
Baylor College of Medicine,
USA
Rahim Rezaie
Research Fellow, Rotman School of Management
University of Toronto
and Asia Pacific Foundation of Canada (Vancouver), Canada
Robert Braithwaite
CEO
Luqa Pharmaceuticals,
China
Robert Chen
Senior Director, Global Strategy & Partnering
Genor Biopharma,
China
Sally Sha
Director Business Development
Tigermed,
China
Samantha Du
Managing Director
Sequoia Capital,
China
Simone Song
Executive Director, IBD
Goldman Sachs (Asia) L.L.C,
Hong Kong
Wu Chun
Partner and Managing Director
Boston Consulting Group,
Hong Kong
Yajiong Xue, PhD
Director
Center for Healthcare Management Systems
Associate Professor of MIS, College of Business, East Carolina University, USA
Ying Luo
Chairman and CEO
Shanghai Genomics, Inc.,
Chairman, Beijing Continent Pharmaceuticals, China
Yariv Hefez
Vice President, Business Development and Alliance Management, Biosimilars
Merck Serono, Switzerland
Zhihao Yu
Analyst
Lux Research Inc., China
Zheng Li
General Manager
Lundbeck Research, China
Dr. Jochen Tannemann
Sr. Sales Development Manager
Elsevier Information Systems GmbH, Germany

Speakers Bio

Barry Bernstein, MD
Global Head of Infectious Disease Development
Abbott Laboratories, USA

Guoqing Cao got his B.S. in biochemistry from Fudan University in 1987. He entered the graduate program in biochemistry of The Ohio State University in 1990 and obtained his PhD in 1995. From 1995 to 1999, he did his postdoc training with Nobel Laureates Dr. Michael Brown, Dr. Joseph Goldstein and Dr. Helen Hobbs at University of Texas, Southwestern Medical Center at Dallas on cholesterol metabolism and cardiovascular diseases. In 1999, he joined the cardiovascular and metabolic disease division of Lilly Research Laboratories of Eli Lilly & Company as a senior biologist and was promoted to principle research scientist, research advisor and senior research advisor in following years. He is currently serving as the vice president of biology for Jiangsu Hengrui Medicine. Guoqing Cao led the efforts in developing three compounds in clinical studies, including evacetrapib that is currently in phase III trial. He has also published more than 70 papers in top peer-reviewed journals and has given more than 40 talks in international meetings and universities. He was recognized by Lilly Research Laboratories with the President Award in 2009 and also a National 1000 Plan Distinguished Expert in 2012 by the central government of China. He is currently an adjunct professor of State University of New York, Downstate Medical Center and a board member of The Deuel Conference on Lipids.


Binhui (Ben ) Ni
Head of Scouting & Partnership
Sanofi Aventis,
China

Binhui (Ben) has over 17 years of pharmaceutical R&D experience in US and Asia/China. He served at senior scientific and managerial positions in several global companies in the areas of preclinical drug development and clinical operations, including Eli Lilly (US, Action group Chair), S'BIO (Chiron-Singapore JV, Singapore, VP/ head of Biology) and Covance China (General Manager, China). Ben has >40 publications in journals including Science, PNAS and served as adjunct professors in several universities (Dept of Neurology, Indiana University Medical School; Dept of Anatomy and Cell biology, Indiana University Medical School) in USA and Singapore (Division of Life Sciences, University of Singapore, NUS). Ben holds a PhD in Molecular Pharmacology from University of Toronto under fellowship and post-doctoral fellowship in Clinical Pharmacology from National Institute of Mental Health


Bon Chul Brian Ku
General Manager
SK Biopharm (Shanghai),
China

After getting PhD from KAIST and joining SK in 1989, Dr. Ku has covered discovery, development and strategy of new drug R&D. Some of pipelines which he led and developed are now Phase 2 in the US. He has been responsible for SK Biopharm (Shanghai) from 2007 and his main jobs are licensing, partnering, outsourcing and sourcing in China with a strong pharma network both in Korea and China.


Carl Firth
Chief Executive Officer
ASLAN Pharmaceuticals, Singapore

Dr Carl Firth is Founder and CEO of ASLAN Pharmaceuticals, an Asia enabled pharmaceutical company that develops novel medicines for global markets. Previously, he was Head of Asia Healthcare at Bank of America Merrill Lynch, supporting public and private financing of healthcare companies across the region and advising on M&A transactions. Prior to joining the banking industry, he worked for AstraZeneca for nearly 10 years. In2007, he was the Regional Business Development Director, AsiaPac, and a member of the regional management team. From 2004-6, Carl led new product development and business development in AstraZeneca China, based in Shanghai, where he was responsible for the development of new products for the China market and local in licensing activities. Carl has held positions in other commercial areas in the UK, including acquisitions, licensing and competitive intelligence, and has over 5 years of pharmaceutical R&D experience. Carl is an advisor to the Singapore-MIT Alliance for Research and Technology Innovation Centre and several life science companies in Asia. He is a regular speaker and Chair at international conferences. Carl holds a PhD from Cambridge University in Molecular Biology (Trinity College), an Executive MBA from London Business School and a degree in Molecular Biology from Cambridge University.


Cezary Statuch MD
Vice President, Head of China R&D
Bristol-Myers Squibb,
China

Dr. Cezary Statuch’s career in the pharmaceutical industry spans more than 20 years. Following graduation from Medical
School in Poland, he practiced internal medicine in both Poland and the UK. Throughout most of his career in the pharmaceutical industry, Dr. Statuch has focused on developing clinical research capabilities and expanding the geographical footprint within emerging markets. Having successfully started up clinical operations in Central and Eastern Europe, Dr. Statuch relocated to Singapore where he established the BMS hub for clinical research in Asia. During that time he also managed company activities in Latin America. In April 2006 he was offered a challenge to bring BMS’s expanding pipeline to China. In 2009 his responsibility expanded to include the region of Emerging Markets and Japan. He returned to China in 2011 to head the rapidly expanding R&D organization.


Chen Chen
CEO
Sundia MediTech, China

Dr. Chen has a PhD in Organic Chemistry from the Shanghai Institute of Organic Chemistry, China. Dr. Chen spent 15 years at Neurocrine and achieved many outstanding scientific and industrial accomplishments, including development of two small molecule antagonists, NBI-42902 and elagolix (aka NBI-56418), of the gonadotropin-releasing hormone receptor into clinical studies. He designed, synthesized and developed NBI-30775 (R121919), a small molecule antagonist of the corticotrophin-releasing factor receptor as the first-in-class compound advanced into clinical trials for depression/ anxiety. Dr. Chen also discovered NBI-31772, the first small molecule inhibitor for the insulin-like growth factor-I/IGF-binding protein. In addition, Dr. Chen identified

the first selective antagonist of the melanocortin-5 receptor, and discovered numerous agonists and antagonists for the melanocortin-4 receptor for eating disorders. Dr. Chen has served as Sundia's Senior Vice President since 2009. And he has been appointed as CEO of Sundia in 2012. Dr. Chen has so far published near 130 scientific papers in peer-reviewed journals. He has written numerous review articles on the topics of drug discovery and medicinal chemistry. He is the co-inventor of over 25 US patents.


Frank Shen
Divisional Vice President, Statistics & Data Management
Abbott Laboratories,
USA

Dr. Shen returned to US from China in April 2011 and joined Abbott Global Pharmaceutical R&D as a member of the R&D Pipeline Leadership Team and Divisional Vice President of Data & Statistical Sciences to lead 250 quantitative scientists globally in supporting drug discovery and development. Prior to join Abbott, he was the Asia-Pacific Head of Biometrics for Roche Global Pharma Development based in Shanghai and co-founder of the first full-functioned drug development center in China. With his passion as a drug developer to bring China into global scheme, he spent nearly four years in China not only led the establishment and enhancement of Biostatistics, Programming Analysis, Data Management, Pharmacometrics, Clinical Study Management, and Epidemiology professions in China with close interactions with the SFDA, but also led Roche’s development teams that bring new drugs to China NDA filing and approval.


Guoqing Cao
Vice President of Biology
Jiangsu Hengrui Medicine, China

Guoqing Cao got his B.S. in biochemistry from Fudan University in 1987. He entered the graduate program in biochemistry of The Ohio State University in 1990 and obtained his PhD in 1995. From 1995 to 1999, he did his postdoc training with Nobel Laureates Dr. Michael Brown, Dr. Joseph Goldstein and Dr. Helen Hobbs at University of Texas, Southwestern Medical Center at Dallas on cholesterol metabolism and cardiovascular diseases. In 1999, he joined the cardiovascular and metabolic disease division of Lilly Research Laboratories of Eli Lilly & Company as a senior biologist and was promoted to principle research scientist, research advisor and senior research advisor in following years. He is currently serving as the vice president of biology for Jiangsu Hengrui Medicine. Guoqing Cao led the efforts in developing three compounds in clinical studies, including evacetrapib that is currently in phase III trial. He has also published more than 70 papers in top peer-reviewed journals and has given more than 40 talks in international meetings and universities. He was recognized by Lilly Research Laboratories with the President Award in 2009 and also a National 1000 Plan Distinguished Expert in 2012 by the central government of China. He is currently an adjunct professor of State University of New York, Downstate Medical Center and a board member of The Deuel Conference on Lipids.


Ian Lloyd
Editorial Director, Preclinical Drug Information
Citeline, UK

Ian has worked on the Pharmaprojects/Pipeline database, which tracks all drugs moving through the R&D process, for more than 25 years, providing him with a clear perspective and a comprehensive overview of what is really happening in the pharma industry. Having graduated from the University of Bristol with an honours degree in Biochemistry, Ian conducted postgraduate lab research in molecular biology before joining PJB Publications, the initial home of Pharmaprojects, in 1987. Now part of the Informa business Citeline, Ian became Editorial Director in 2006 and has continued to work on the drug database in tandem with Citeline’s other renowned business intelligence services, including Trialtrove and Sitetrove. Ian’s years of experience give him the ability to judge the impact which a major event in the pharma pipeline might have on the market.  In addition, he is able to tap into data which allows him to quickly spot emerging trends in the pharmaceutical industry.


James Garner, MD
Vice President and General Manager
Takeda Global Research and Development Center (Asia),
Singapore

Dr. James Garner is currently Vice President and General Manager at Takeda Global Research & Development Center (Asia), a regional R&D hub from which Takeda manages clinical studies across the Asian region. Prior to joining Takeda, he was Regional Medical Director for Asia with Quintiles, a contract research organisation, and he has also held regional and global positions with several NASDAQ-listed biotechnology companies. He previously worked as a corporate strategy consultant with Bain & Company, and as a hospital doctor. Dr. Garner completed his medical studies at St. Mary’s Hospital Medical School in London, and also holds an MBA from the University of Queensland, Australia, together with a Graduate Certificate in Applied Finance and Investment from the Financial Services Institute of Australasia. He is a Fellow of the Royal Society of Medicine and a member of the Australian Pharmaceutical Physicians Association. In 2008, he was named a ‘Young Executive of the Year’ by the Australian Financial Review’s BOSS magazine.


James Huang
Managing Partner
KPCB, China

James Huang joined Kleiner Perkins Caufield & Byers China as a Managing Partner in 2011 and focuses on the firm’s life sciences practice. His main investment interests are innovation around China’s growing healthcare markets and helping entrepreneurs build companies. Before coming to KPCB China, James was a Managing Partner at Vivo Ventures, a venture capital firm specializing in life sciences investments. While at Vivo, James led numerous investments in China. Before joining Vivo in 2007, James was President of Anesiva, a biopharmaceutical company focused on pain-management treatments. During his 20-year career in the pharmaceutical and biotech industry, he also held senior roles in business development, sales, marketing and R&D with Tularik Inc. (acquired by Amgen), GlaxoSmithKline LLC, Bristol-Meyers Squibb and ALZA Corp. (acquired by Johnson & Johnson). James received an M.B.A. from the Stanford Graduate School of Business and a B.S. degree in Chemical Engineering from the University of California, Berkeley.


Jason Mann
Head China Healthcare Equity Research
Barclays Capital,
Hong Kong

Jason Mann, MD, PhD leads Barclays’ healthcare team advising institutional investors on the pharmaceutical / healthcare sector in China. He is based in Hong Kong.

Dr Mann joined Barclays Capital from Mann Biotechnology Ventures, an independent consultancy where he advised hedge funds and venture capital firms on investments in the China and US pharmaceutical/healthcare space. He also worked at SciClone Pharmaceuticals, the largest China-focused US therapeutics company and advised senior management as a consultant in the biopharma and healthcare sectors at McKinsey & Company. Previously, he lived in Wuhan and Changchun, as his parents were among the first “foreign experts” invited by Deng Xiaoping at the beginning of the reform period. Dr Mann has an MD and PhD from Vanderbilt University as well as an AB from Harvard.


Jim O’Mara
Vice President Corporate Development
Ironwood Pharmaceuticals,
USA

Jim O’Mara has served as Ironwood's Vice President of Corporate Development since January 2006, and has been a leader in business development since joining the Company in October 2001. Prior to joining Ironwood, O’Mara was vice president of corporate development at Cozint Interactive, a healthcare marketing services company. He also served as a vice president for MPM Capital where he managed business development strategies and interactions for biotechnology and pharmaceutical companies. Earlier in his career, O’Mara held different sales and marketing positions at both Merck and Centocor. O’Mara earned a BS in pharmacy from the Massachusetts College of Pharmacy.


Jun Bao
Director of Worldwide Business Development
GlaxoSmithKline, China

Dr. Jun Bao has substantial experiences in drug discovery and development, technology transfer, licensing and business development, venture investment, start-up and corporate finance. He is currently a director of Worldwide Business Development, Head of China at GlaxoSmithKline. In this capacity, he is responsible for business development and venture activities in China. Previously he was a Director of Corporate Development and Financial Planning in Onyx Pharmaceuticals, a US biotech company focusing in cancer
therapy. Prior to Onyx, he was an Associate Director of Business Development in ICOS

Corporation based in Seattle. At ICOS, he was responsible for licensing and business development activities in oncology. Prior to ICOS he was a Senior Manager of Business Development in Cell Therapeutics, Inc., a Seattle-based oncology biopharmaceutical company. Dr. Bao also worked as a finance manager in Procter & Gamble based in Cincinnati. Dr. Bao received a BS in Microbiology from Shandong University and a PhD in Neuroscience from University of Kansas. He completed his postdoctoral fellowship in Johns Hopkins University. In addition, he received an MBA in Finance from University of Chicago. He also founded two biotech start-up companies.

Ka-Kit Hui, MD, FACP
Wallis Annenberg Chair in Integrative East-West Medicine, Chair, Collaborative Centers for Integrative Medicine, Professor, Founder & Director
Center for East-West Medicine, Department of Medicine, UCLA,
USA

Dr. Hui, a Fellow of the American College of Physicians, is an internationally acclaimed scholar and board-certified in Internal Medicine and Clinical Pharmacology, with an expertise in Geriatrics. He is a recognized authority on Chinese Medicine and integrative medicine, and is bi-lingual in Chinese and English. Dr. Hui founded the UCLA Center for East-West Medicine in 1993, which it was one of the first integrative medicine centers in the United States. He has developed a model system of comprehensive care that is a patient-centered, problem-solving approach emphasizing health promotion, disease prevention, treatment, and is safe, effective, affordable and accessible to all. Dr. Hui, as a recipient of the Faculty Developmental Award in Clinical Pharmacology by the Pharmaceutical Manufacturer’s Association Foundation in the 1980s, has worked with the National Institute of Health, U.S. Food and Drug Administration, World Health Organization, Blue Cross, Blue Shield, Health Net, the pharmaceutical industry, medico-legal firms, and the media. He has published over 100 articles, papers, abstracts and book chapters, in English and Chinese. Dr. Hui serves on the editorial boards of the Chinese Journal of Integrative Medicine, Journal of Chinese Medicine, Journal of Chinese Integrative Medicine, China Anesthesia and Analgesia, eCAM Journal, Journal of Traditional and Complementary Medicine, Cancer Survivorship, and Integrative Medicine Research.  He has been featured in print, radio, television, cable news, and on CCTV, ABC, CBS, NBC, PBS and the Discovery Channel. Dr. Hui has been awarded numerous grants in areas including integrative medicine, acupuncture, herbal medicine, asthma, aging, autonomic system regulation, pharmacology and medical education. He also holds honorary and visiting professorship in universities in China, Hong Kong, Korea, and Australia. Born and raised in Hong Kong, Dr. Hui earned his BS and MD degrees at UCLA. He completed his post-graduate training in Internal Medicine and Clinical Pharmacology at UCLA’s Hospitals and Clinics.


Mikael Brönnegård, MD, PhD
Associate Professor, and Chief Executive Officer
NeuroVive Pharmaceutical AB,
Sweden

Mikael Brönnegård has an MD, PhD degree from the Karolinska Institute, in Stockholm Sweden where he still holds a position as Associate Professor. Mikael is a specialist in Paediatrics and Paediatric Endocrinology and Diabetes, and has extensive experiences in clinical research and in basic science / research including molecular biology, protein biochemistry and immunology. His reference list includes over 100 publications in scientific journals, textbooks of Medicine and business reviews. Mikael also has several years of pharmaceutical industry experience at both local market company (Clinical Research Physician and Medical Director, Eli Lilly) and corporate level including global business management (Vice President and Head of Global Medical Affairs, Pharmacia Corporation). He has a broad experience from operative positions in the biotechnology and pharmaceutical industry. Mikael has been working at an executive level in the venture capital industry focusing on start-up and early stage investments (InnovationKapital) and as director of business development within the biotechnology and life sciences sector in UK and US. Mikael has been sitting on several boards and still holds a number of board positions.


Ming Guo, PhD
Co-Founder & COO, Ascentage Pharma
and General Manager, Small Molecule Drug R&D Center, China Medical City, China

Dr. Ming Guo has been working in the biotech and pharmaceutical industry for over 20 years. At Pfizer (1996-2005), Dr. Guo led many NCE drug R&D projects at various technical and project levels.  At Ascenta, Dr. Guo was Vice President of Pharmaceutical Sciences & Manufacturing, and also General Manager of Ascenta (Shanghai) R&D Center which engaged in NCE drug R&D in China since 2005.  Dr. Guo played additional important roles at Ascenta in strategic planning, business development, fund raising (close to $100M), global out-licensing deals (e.g., $398M global licensing deal with Sanofi-Aventis in 2010 and another undisclosed deal with Debio in 2011). During 2002-2005, Dr. Guo was an Overseas Advisor for Beijing Zhongguangcun Biotech Park.  He has been graduate student adviser and teaching for the Master of International Pharmaceutical Engineering Management (IPEM) program at Peking University since 2007.  Dr. Guo is an Independent Director at Porton Corporation (Chongqing, China) since 2010, participating in the process of its IPO approval in 2012.  Dr. Guo has many scientific publications and patents, and has frequently been invited as speaker or panelist at international professional and business conferences. 


Pui-Kwong Chan, PhD
Professor, Department of Pharmacology
Baylor College of Medicine,
USA

Dr. Pui-Kwong Chan received a BS and a M. Phil. degree from The Chinese University of Hong Kong and a PhD degree from the University of Toronto.  He is currently a Professor at Baylor College of Medicine, Houston Texas, U.S.A.  His research had been in anti-cancer drug mechanisms, nucleolar proteins and Nucleophosmin/B23.  Most recently his research is focused on cytotoxic saponins isolated from Chinese herbal medicine. On this topic, 8 US patents has been awarded.


Rahim Rezaie
Research Fellow, Rotman School of Management
University of Toronto
and Asia Pacific Foundation of Canada (Vancouver), Canada

Dr. Rahim Rezaie is a Research Fellow at the Rotman School of Management and the Munk School of Global Affairs at the University of Toronto, and a Post Graduate Research Fellow at the Asia Pacific Foundation of Canada. He studies biotechnology and pharmaceutical innovation with a focus on China, India and Brazil, and the role that these countries play in addressing global health needs. He also examines the implications of the rising innovation capacity in the emerging markets for public policy and business strategy in Canada and the US. He has published a series of articles on vaccine, diagnostics and medicinal innovations by domestic companies in China, India and Brazil in the Nature Biotechnology, and elsewhere. His practical experiences include genetic testing for a host of hereditary conditions as well as in pharmaceutical regulatory affairs. Dr. Rezaie received a master of biotechnology degree and a doctoral degree from the University of Toronto, where he was the recipient of the Banting and Best Canada Graduate Scholarship.


Robert Braithwaite
CEO
Luqa Pharmaceuticals,
China

Robert is CEO & Co-Founder at Luqa Pharmaceuticals, a China-based specialty pharmaceutical company with operations across Asia, building a best in class portfolio of innovative products. Prior to founding Luqa, Robert was Chief Representative for Almirall in China and headed the Asia-Pacific region. Robert started his career in the pharmaceutical and device industry over 18 years ago working at Alcon Laboratories.


Robert Chen
Senior Director, Global Strategy & Partnering
Genor Biopharma,
China

Mr. Robert Chen is currently Senior Director, Head of Business Development at Genor Biopharma, a dedicated mAb product development and manufacturing company in China. His main responsibilities include business development, corporate strategy, and intellectual property management.  He has more than 12 years of industrial experience in the biopharmaceutical industry. Prior to joining Wison, he worked for 2 years in a biopharmaceutical venture capital company, and developed his expertise in business development, company strategy and intellectual property management with two other biotechnology companies. He finished his MS study of Neurobiology at the Chinese Academy of Sciences, and obtained his Bachelor of Biology from Wuhan University. He also spent one year studying as a PhD candidate at the University of Florida, and completed a nearly one-year Executive Development Program (EDP) at Fudan University School of Management.


Sally Sha
Director Business Development
Tigermed,
China

Sally Sha used to be Chief Doctor in Shanghai Xin Hua Hospital, affiliated with Jiao Tong University. She now has over 18 years of management experience in Medical, Medical Marketing, Marketing and Professional Marketing in AZ, Roche and J & J. Since 2008, Sally works as the Business Development Director and project director for Hangzhou Tigermed Consulting Co.,Ltd to take charge of the drug development with MNC and leading domestic pharmaceutical companies for innovative drugs in the field of oncology, CV and CNS and diabetes. With her support, there are more than 30 regional trials, global trials with multicenter sites conducted in China and regions by promising performance of sites for the innovative and imported new drugs. Sally Sha obtained Master degree of Medicine from the Shanghai Second Medical University, (Jiao Tong University) in 1991, and then in 2004, she obtained Diploma in Management Program–CEIBS (China Europe International Business School), Shanghai, China.


Samantha Du
Managing Director
Sequoia Capital,
China

Samantha Du is a Managing Director of Sequoia Capital China, responsible for healthcare investment. Prior to joining Sequoia China in 2012, Dr. Du founded and served as the Chief Executive Officer of Hutchinson MediPharma (HMP) for ten years. She was also the co-founder and Chief Scientific Officer of Hutchinson Chi-Med (LSE:HCM), a London AIM-listed company. She has built Hutchison Medipharma from scratch to a leading china based world renowned biotech company with rich product in both oncology and autoimmune. Under her leadership, the company has pioneered China’s FIH green channel, established first of its kind collaborations with multinational companies including JNJ, Lilly, PG etc. She was both on the planning committee and expert panel of the 12th five year state healthcare key projects. Prior to Hutchison, Dr. Du worked as a US-based executive of Pfizer’s global R&D and Metabolic business. She was involved in the development of multiple early and late stage product development, of which two were approved and launched globally. While at Pfizer, she served on FDA’s working committee. She is currently an Adjunct Professor at Fudan University’s School of Pharmacy and Chair of Pudong Drug Innovative Committee. Dr. Du is a recipient of Shanghai’s 2010 Magnolia award (an honorable citizenship award) and recipient of Shanghai’s thousand talent program. She was featured by many magazines and world renowned newspapers, including WSJ and Forbes and was on the cover of Forbe’s Asia in 2007.


Simone Song
Executive Director, IBD
Goldman Sachs (Asia) L.L.C,
Hong Kong

Simone joined Goldman Sachs in October 2010 and has been Executive Director of the Investment Banking Division.  She is in charge of the China Healthcare business. Prior to joining Goldman Sachs, Simone has been in the following positions:
Jan – Sep 2010, Managing Director of Cowen Group
2004 – 2010, Advisory Committee Member of the AXA Investment Managers
2004 – 2006, Advisor of the Executive Director Board for AXA Asia Pacific Holdings
1997 – 2002, Vice President of Financing for KGI Capital Asia Limited

Simone also holds a Master Degree in Economics from Claremont Graduate School and Bachelor Degree in Economics from Fudan University


Wu Chun
Partner and Managing Director
Boston Consulting Group,
Hong Kong

Chun Wu is a Partner and Managing Director in Hong Kong office. She has over 10 years consulting services to healthcare clients. As a core member of global healthcare practice, Dr. Wu has served biopharma, vaccine and HC provider clients on corporate strategy, portfolio strategy, business development, market access, sales and marketing effectiveness and organization topics. Also a core member of strategy and sales & marketing practices, Dr. Wu has expertise on topics of emerging market growth strategy, sales force effectiveness and innovative business models.


Yajiong Xue, PhD
Director
Center for Healthcare Management Systems
Associate Professor of MIS, College of Business, East Carolina University, USA

Yajiong Xue is the Director of Center for Healthcare Management Systems and Associate Professor of MIS of College of Business at East Carolina University. Dr. Xue received her PhD in Management Information and Technology Innovation from Auburn University. She has over 15 years academic and industry work experiences in China and US. She has served on the expert panel of numerous drug innovation and policy projects funded by Chinese governments and international agencies. She is a research fellow of International Center of Medical Administration at Beijing University. She has over 50 publications on peer-reviewed journals and conference proceedings. Her research has appeared in academic journals such as Drug Discovery Today, Journal of Public Health Policy, MIS Quarterly, Information Systems Research, and many others. Her current research interests include technology innovation, drug policy, and healthcare informatics.


Yariv Hefez
Vice President, Business Development and Alliance Management, Biosimilars
Merck Serono, Switzerland

Yariv has more than 12 years’ experience in Business Development, Strategic Partnering, Alliance Management, M&A and Change Management, within the biotechnology, pharmaceutical and professional service industries. Yariv has a Master in Commercial Law and a MBA from IMD business school in Switzerland. Yariv established a successful professional service company before joining Merck Serono in 2008, where he has been leading Licensing, M&A and special strategic projects.  In 2009 Yariv initiated an innovative outsourcing model that transformed the way in which Merck Serono outsources clinical trials and in June 2010 Yariv was awarded the Merck Serono CEO award for his key role in initiating and leading this project.


Ying Luo
Chairman and CEO
Shanghai Genomics, Inc.,
Chairman, Beijing Continent Pharmaceuticals, China

Dr. Ying Luo joined Peking Union Medical College to study medicine in 1982 and earned his PhD degree of Molecular Biology and Biochemistry at the University of Connecticut Health Center of the United States in 1986. His postdoctoral research was on HIV gene regulation at the University of California at San Francisco in 1992. From 1993 to 2000, he took various positions in biotech companies in the San Francisco Bay Area, including Aviron, Clontech, and Rigel. In 2001, he returned to China as CEO and founder of Shanghai Genomics, Inc. From 2001, Dr. Luo has led three Chinese National “863” Hi-Tech Development Projects, 1 national “Major New Drug Development” project, and multiple Shanghai local government research grant projects. In his career, he had co-authored more than 35 research publications in leading international journals of life sciences and wrote several review articles covering the changing trends of the Asian biotechnology industry. In 2005, Shanghai Genomics merged with GNI, a Tokyo-based drug development company and Dr. Luo has also been CEO of the combined companies since 2007. His venture in China has received worldwide media coverage including the front page of The Wall Street Journal in 2003, London Financial Times, Nikkei CNBC, Shanghai TV, and Beijing TV channels. In 2007, Dr. Luo was awarded the Magnolia Silver Medal by Shanghai Municipal Government for his contribution to the economic development and modernization of Shanghai.


Zheng Li
General Manager
Lundbeck Research, China

Dr. Zheng Li is the General Manager and Site Head of Lundbeck Research China located in Shanghai.  In his current role, Zheng established the legal entity (a WFOE – wholly foreign owned enterprise), built up capability and is responsible for the full operation of Lundbeck Research China site.  Dr. Li was at Lundbeck Research USA (Paramus, New Jersey, USA) since 2009, served as disease area team leader, research project leader, and head of a drug discovery unit specializing in mechanistic and translational research.

Previously, Zheng worked at Parke-Davis / Pfizer (Ann Arbor, Michigan and Groton, Connecticut, USA) from 1999-2009.  He served as lab head of a neuropharmacology lab and project leader, directed and supported to both early and late stage drug discovery projects that contributed to the nomination of 8 clinical candidates (two achieved Ph II proof of concept), one NDA approval and supported life cycle management of Neurontin® / Lyrica® franchise. Zheng obtained his B. Sc. degree in Biophysics from the University of Science and Technology of China in Hefei, and Ph.D. degree in Neuroscience from University of Massachusetts at Amherst.  He completed his postdoctoral training in developmental neurobiology and molecular genetics at the University of Michigan, Ann Arbor. 


Zhi-Qiang Ning, MD, PhD
Cofounder, VP R&D
Shenzhen Chipscreen Biosciences Ltd, China

Dr. Ning obtained his Ph.D. in immunology from University of London, UK, in 1996. Before joined Chipscreen Biosciences in 2001, he was a Research Assistant Professor at the University of Cincinnati, USA, specialized in the areas of immunology and cancer/ leukemia research. As a Co-founder and VP R&D, he has actively involved and played an important role in Chipscreen’s R&D programs of innovative drugs against cancer and type 2 diabetes from bench to late stages of clinical development. Dr. Ning has published over 30 papers in international journals, and co-applied over 30 patents in US, PCT and China.


Zhihao Yu
Analyst
Lux Research Inc., China

As an Analyst at Lux Research, Zhihao Yu leads the China BioPharma practice which focuses on covering the spectrum of innovative biopharma activities in China.  Based in Shanghai, Zhihao covers rapidly growing areas such as molecular diagnostics, therapeutics, biomaterials, medical devices, and emerging areas such as bioinformatics and bioprocessing.   Prior to joining Lux Research, Zhihao worked as a postdoctoral research fellow in Cleveland Clinic, one of the top hospitals in the US, exploring nitric oxide biology using advanced spectrophotometric techniques.  He has a number of published research articles in leading peer reviewed journals.

Zhihao Yu received his PhD in biochemistry from the University of California at Davis, utilizing crystallographic techniques to study protein structure-function relationships. Zhihao is a graduate of Nanjing University with a B.S. in Chemistry and a MS in Analytical Chemistry.


Al Dampier
Chief Executive Officer
Dampier Consulting Group LLC, USA

Al Dampier is a nationally recognized leader in the healthcare industry where he has more than 25 years experience with accomplishments in Consulting, Healthcare, Management, Health Informatics, and Managed Care. Working with Senior Executives, Al provides insight and innovative solutions to impact the bottom line. His clients include major pharmaceutical, biotech, specialty pharma, healthcare and emerging organizations. Al co-authored “Success Simplified” with Stephen Covey and you will often find him talking to organizations and teams discussing a “Roadmap for Your Journey.” His talks exemplify the importance of having the right people on the team, teamwork and a strategic framework for growth. Al creates novel processes in Vision, Leadership, Communication and Organizational Performance to meet the individual demands of the client, partnering with HR Colleagues and Senior Management for shared accountability coupled with a strategic framework for growth. Through his dynamic consulting techniques, Al is available to bring his unique and relevant perspectives to you and your team.


Prof. Aamir Shahzad
MD
, Director of Administration,
International Society for Translational Medicine (ISTM),
Austria

Currently based in Vienna, Austria, Prof. Shahzad is one of the pioneers in the translational medicine field. Prof. Shahzad currently serves as Director of Administration for ‘International Society for Translational Medicine’ (ISTM) and Chair for Translational Medicine SIAC group at ‘Dug Information Association’ (DIA). He also serves as editor-in-chief for the journals Molecular Medicine & Therapeutics and Translational Biomedicine. He is visiting faculty member at Harbin Medical University and Wenzhou Medical College. Prof. Shahzad has participated in establishing translational medicine infrastructures for several organizations.


Angela Luo
Senior Partner,
Beijing Long An Law Firm Shanghai Branch
, China

Angela Luo was admitted to practice as a lawyer in China in 1996. She set up her own law firm in 2003. In July 2011, her law firm merged with Beijing Long An Law Firm and she became a senior partner. She has over 16 years legal experiences in electronics industry, medical, franchising, media, trading, logistics industries, especially in providing legal service to those wholly-foreign invested companies, joint ventures. She has an insight, good communication and bilingual English-Chinese negotiation skills.


Betty Su
Vice President,
Boston Healthcare Associates,
China

Betty Su is a Vice President at Boston Healthcare Associates and leads the Firm’s activities in the Asia Pacific region out of the Shanghai office. Betty specializes in market access services providing business strategy consulting, regulatory consulting and registration services for life sciences companies located in China or planning to enter the China market. She has helped several biopharmaceutical, medical device and in vitro diagnostics companies in the areas of pricing and reimbursement, sales and marketing, and overall market development and growth strategies.

Prior to joining Boston Healthcare, Betty was the Managing Director and founding member of RXB Consulting, a professional service firm focused on the healthcare industry facilitating Foreign-Sino business development opportunities across borders. Betty also worked several years at AstraZeneca in China in marketing, government affairs, and corporate communications functions.

Betty completed her international MBA degree through a joint program between Norwegian School of Management and Fudan University in 2007 and held a bachelor degree in the international marketing from Shanghai Institute of Foreign Trade.


Ian Haydock
Asia Editor,
Scrip Intelligence,
Japan

Ian Haydock has more than 20 years’ experience covering the pharmaceutical industry in Japan and Asia for Scrip Intelligence (part of Informa plc), having first come to Japan in 1990 to open the Scrip’s first full-time editorial office in Asia. He provides analysis of a broad range of topics affecting the regional and global prescription drug industry, spanning coverage of R&D findings to policy and regulatory news and corporate developments. Ian formerly worked in the regulatory affairs field in the agrochemical industry in the UK after graduating from King’s College London, and grew up in Hong Kong.


Jimmy Zhang, PhD
Managing Director, MSD Early Investments – Greater China ,
Merck & Co., Inc., China

Dr. Jimmy Zhang is responsible for Merck's venture capital investments, licensing, acquisitions, external research collaboration, and alliance/partnership management in Greater China. Before joining Merck, Jimmy was a Senior Vice President at Synergenics, LLC, a professional service and venture firm founded and led by Dr. Bill Rutter, one of the founding fathers and pioneers of the biotech industry. Jimmy was also the executive vice president of ReLIA Diagnostic Systems and its wholly-owned China subsidiary ReLIA Biotechnologies (Shenzhen). Jimmy was previously a consultant at McKinsey & Company traveling and working in China, US and Germany, a registered patent agent in the Palo Alto office of Morrison & Foerster, and a project manager at Chiron Corporation (now part of Novartis). Jimmy received his BS in biochemistry from Nanjing University, and PhD in biomedical sciences from the University of Texas Southwestern Medical Center at Dallas, where he worked closely with two Nobel Laureates. While studying his MBA in MIT Sloan School of Management, Jimmy was elected as the treasurer of MIT Graduate Student Council. Jimmy published in Cell, Nature, Neuron, and JBC, and holds multiple patents. He’s a founding member and the current Chairman, Board of Directors of BayHelix Group, a prestigious non-profit organization of Chinese life sciences business leaders. Jimmy is also the Strategic Advisor to both ChinaSF and China Committee of Bay Area Council, and a guest/adjunct professor at Tongji University, Shanghai.


Li Chen
President and Chief Executive Officer,
Hua Medicine,
China

Dr. Li Chen is the co-founder and CEO of a newly established drug discovery and development company, Hua Medicine, which brings clinically differentiated medicine to the patients in China and rest of world. Before Dr. Chen founded Hua Medicine, he was the Chief Scientific Officer and Head of Research at Roche R&D Center (China) Ltd. and a member of Roche Pharma Research Leadership Team. As a founding Director in this position, Li was responsible for development and implementation of China drug discovery strategy, creation of China discovery portfolio, and management of China operation, including Biology, Chemistry, Pharmacology, Discovery Technology, Drug

Supply and Drug Safety. He has developed a “Collaborative Innovation” model through integration of over 100 scientist-based China partnership with academic institutes, biotech, contract research organizations and clinical development organizations. Li was the President of the Sino-American Pharmaceutical Professionals Association (SAPA) in 2001, and is now a member of the SAPA Board of Directors. He is currently an adjunct professor of Chemical Biology at Tongji University. He has over 80 publications in numerous peer-reviewed scientific journals and in patent literature.


Peter Peizhi Luo
Chief Executive Officer,
Adagene Inc.,
China

Dr. Peter (Peizhi) Luo is a serial entrepreneur passionate about innovative biotechnology and product development. Currently, he is the founder and CEO of Adagene, an emerging biopharmaceutical company focused on novel antibody technology and product pipeline development with financial support by leading US and Asia life Science Investors. Dr. Luo was the Director of Biologics at Merck & Co., Inc. and Chief Technology Officer of Abmaxis Inc., a wholly owned subsidiary of Merck & Co; he developed Merck antibody discovery and engineering platform for Merck novel biologics discovery. Prior to the acquisition of Abmaxis by Merck in 2006, Dr. Luo was the Cofounder, Chief Technology Officer, President and a Board Director of Abmaxis Inc. He played a key role in building the Abmaxis management and scientific teams, and in shaping its technology and business strategies. Dr. Luo was the first lead scientist in Xencor focusing on computational protein design and protein laboratory.

Dr. Luo completed his postdoctoral research in protein folding at Stanford University. He received his PhD in Chemistry from the University of Chicago, a MS degree in applied physics from The Institute of High Energy Physics of the Chinese Academy of Sciences, and a BS degree in applied chemistry from Peking University.


Seth Goldenberg
Senior Principal Scientist,
NAMSA
, USA

Seth J. Goldenberg Ph.D. is currently a Senior Principal Scientist with NAMSA and Former Regulatory Chemist with the FDA, holds a Ph.D. in Pharmacology from the University of Washington and a M.S. from the School of Biomedical Engineering at Drexel University. After leaving the FDA Dr. Goldenberg founded Asia Pacific Bio Intelligence, with offices in Philadelphia, PA (USA) and Shanghai (China), which focused on regulatory and quality consulting with firms in the US and China to overcome hurdles and resolve issues with regulatory bodies. Recently Dr. Goldenberg has joined NAMSA, the premier global medical research organization providing expert regulatory, clinical, and compliance services to medical device and healthcare product manufacturers around the world.


Dr. Jochen Tannemann
Sr. Sales Development Manager
Elsevier Information Systems GmbH, Germany

Jochen studied Chemistry at University Duisburg (Germany) and McMaster University Hamilton (Canada)  and received his PhD in Organic Chemistry from University Dortmund (Germany).

After 4 years in sales of specialty chemicals he joined MDL Information Systems, an Elsevier Company, as Product Manager for the CrossFire Databases and Software. Today, Jochen is Sales Development Manager in the Reaxys Product Team, focusing on the interaction of the Market and Sales with the Product Team. One of Jochen’s major accomplishments was to expand the presence of Reaxys in the Asian market, e.g. by installing the first CrossFire consortium for academic customers hosted at Beijing University.

Acknowledgements

The organizers would like to thank all speakers and panelists in helping to shape the agenda.

We would also like to acknowledge and thank a number of industry professionals for their assistance during the research and development process. It is only through the generous time and feedback provided by industry that we can continue to develop well-researched, relevant and interesting programmes. Thank you to:

  • Salman Bokhari, Managing Director, SIDRAPEX Pte. Ltd., Singapore
  • Hans-Jürgen Federsel, Senior Principal Scientist, AstraZeneca, Sweden
  • Douglas Andrews, CEO, Stravencon, UK
  • Ri Ting Allan Liu, Senior Adviser/Vice President, Shanghai Fosun Pharmaceutical Development Co Ltd, China
  • Frank Floether, President, Dr Floether Consulting, Switzerland
  • Andrew A Parsons PhD, Founder & Director, Reciprocal Minds Limited, UK
  • Robert Pollard, Managing Director, PSL Research, China
  • Christine Blazynski, Senior VP, Product Development/Content Strategy, Product Development and Technical Operations, Citeline, USA
  • Litao Zhang, Executive Director, Lead Evaluation, Bristol- Myers Squibb Company, USA
  • Luigi G Martini FRPharmS, MBA, Professor, Chair in Pharmaceutical Innovation, King's College London, UK
  • Ye Hua, Senior Corporate Counsel, Pfizer Global Research & Development Co Ltd, China
  • Mark Chen, Business Development Manager, Bayer Healthcare Co Ltd, China
  • Jennifer Hu, Vice President/Head, Innovation Center China of Global Drug Discovery, Bayer Healthcare Global R&D Center, China
  • Hong Mei Zhang, Senior Business Development Manager, Eisai China Inc, China
  • Becky Lin, Partner, Seed IP Law Group, USA              
  • Jim Joly, PhD, President & CEO, Pharma-GPS, LLC, USA 

To download the latest agenda with all confirmed speakers, click here »

 Register Now
Register Online
+65 6508 2401
+65 6508 2407
Customer Services

 Sponsorship
Download Prospectus

 Co-located With:

 Downloads
Download New Emerging R&D and Clinical Trial Locations White Paper
  Post Event Report

 Quick Links
Agenda
Speakers
Sponsorship
Helpdesk

 Connect Now
Add to Calendar
Add to Favourites
Register for E-update


Produced By
Panel Sponsors  
Bronze Sponsor
 

Exhibitor
   

Supported by
   

Media Partners